open access

Ahead of print
Original paper
Submitted: 2021-05-05
Accepted: 2021-08-19
Published online: 2021-10-06
Get Citation

Tumor necrosis factor alfa (TNFα) and alfa-Klotho (αKL) in children and adolescents with chronic kidney disease (CKD)

Zuzanna Gamrot1, Piotr Adamczyk2, Elżbieta Świętochowska3, Dagmara Roszkowska-Bjanid4, Jakub Gamrot5, Maria Szczepanska5
DOI: 10.5603/EP.a2021.0082
·
Pubmed: 34647605
Affiliations
  1. Unit of Pediatric Hematology and Oncology, Chorzow City Hospital, Poland
  2. Department of Pediatrics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
  3. Chair and Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice
  4. Pediatric Nephrology Ward, Independent Public Clinical Hospital No. 1 in Zabrze
  5. Department of Pediatrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, ul. 3 Maja 13/15, 41-800 Zabrze, Poland

open access

Ahead of print
Original Paper
Submitted: 2021-05-05
Accepted: 2021-08-19
Published online: 2021-10-06

Abstract

Introduction: Chronic kidney disease (CKD) in children, despite the progress in science and medical technology, is still a serious challenge. Early CKD detection gives a chance for immediate therapeutic intervention and lowering the progression of the disease. According to several publications indicating the possible use of alfa-Klotho (αKL) and Tumor Necrosis Factor alfa (TNFα) for the early detection of the disease in adults, an attempt was made to evaluate their usefulness in the pediatric population. Material and Methods: Study group consisted of 42 patients with CKD with the mean age of 10,7 years (18 girls and 24 boys). Control group involved 21 healthy children with the mean age of 8,4 years (11 girls and 10 boys). Anthropometrical parameters and blood pressure were taken, routine biochemical tests were performed in the whole group. The concentration of TNFα and αKL in serum and urine was determined by enzyme immunoassay. Results: Children from the CKD group showed statistically significant difference in serum TNFα and αKL in comparison to the control group. There was no significant relation of evaluated markers to sex, presence of hypertension or proteinuria in children. Mean αKL serum concentration was higher in patients on dialysis compared to the group of conservatively treated children, whereas the values of TNFα in serum and urine as well as the αKL in urine did not differ significantly in these groups. Significant positive correlation was found between serum αKL concentration and serum creatinine, but there was no other correlation between serum αKL or TNFα concentration and any of measured anthropometric and laboratory parameters. Conclusions: Serum TNFα and αKL levels in children with chronic kidney disease although being statistically different comparing to the healthy children group, showed no correlation to the most parameters used for chronic kidney disease evaluation except serum αKL and creatinine. Their usefulness in the early detection of kidney dysfunction in children was not proven.

Abstract

Introduction: Chronic kidney disease (CKD) in children, despite the progress in science and medical technology, is still a serious challenge. Early CKD detection gives a chance for immediate therapeutic intervention and lowering the progression of the disease. According to several publications indicating the possible use of alfa-Klotho (αKL) and Tumor Necrosis Factor alfa (TNFα) for the early detection of the disease in adults, an attempt was made to evaluate their usefulness in the pediatric population. Material and Methods: Study group consisted of 42 patients with CKD with the mean age of 10,7 years (18 girls and 24 boys). Control group involved 21 healthy children with the mean age of 8,4 years (11 girls and 10 boys). Anthropometrical parameters and blood pressure were taken, routine biochemical tests were performed in the whole group. The concentration of TNFα and αKL in serum and urine was determined by enzyme immunoassay. Results: Children from the CKD group showed statistically significant difference in serum TNFα and αKL in comparison to the control group. There was no significant relation of evaluated markers to sex, presence of hypertension or proteinuria in children. Mean αKL serum concentration was higher in patients on dialysis compared to the group of conservatively treated children, whereas the values of TNFα in serum and urine as well as the αKL in urine did not differ significantly in these groups. Significant positive correlation was found between serum αKL concentration and serum creatinine, but there was no other correlation between serum αKL or TNFα concentration and any of measured anthropometric and laboratory parameters. Conclusions: Serum TNFα and αKL levels in children with chronic kidney disease although being statistically different comparing to the healthy children group, showed no correlation to the most parameters used for chronic kidney disease evaluation except serum αKL and creatinine. Their usefulness in the early detection of kidney dysfunction in children was not proven.

Get Citation

Keywords

children; chronic kidney disease; TNF alfa; alfa Klotho; renal replacement therapy

About this article
Title

Tumor necrosis factor alfa (TNFα) and alfa-Klotho (αKL) in children and adolescents with chronic kidney disease (CKD)

Journal

Endokrynologia Polska

Issue

Ahead of print

Article type

Original paper

Published online

2021-10-06

DOI

10.5603/EP.a2021.0082

Pubmed

34647605

Keywords

children
chronic kidney disease
TNF alfa
alfa Klotho
renal replacement therapy

Authors

Zuzanna Gamrot
Piotr Adamczyk
Elżbieta Świętochowska
Dagmara Roszkowska-Bjanid
Jakub Gamrot
Maria Szczepanska

References (38)
  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2012; 3(Suppl): 1–150.
  2. Becherucci F, Roperto RM, Materassi M, et al. Chronic kidney disease in children. Clin Kidney J. 2016; 9(4): 583–591.
  3. Harambat J, van Stralen KJ, Kim JJ, et al. Epidemiology of chronic kidney disease in children. Pediatr Nephrol. 2012; 27(3): 363–373.
  4. Czarniak P, Król E, Szcześniak P. Wybrane aspekty epidemiologiczne przewlekłej choroby nerek u dzieci i młodzieży. Forum Nefrol. 2010; 1: 45–50.
  5. Crump C, Sundquist J, Winkleby MA, et al. Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood: national cohort study. BMJ. 2019; 365: l1346.
  6. Ferris ME, Miles JA, Seamon ML. Adolescents and Young Adults with Chronic or End-Stage Kidney Disease. Blood Purif. 2016; 41(1-3): 205–210.
  7. Kaspar CDW, Bholah R, Bunchman TE. A Review of Pediatric Chronic Kidney Disease. Blood Purif. 2016; 41(1-3): 211–217.
  8. Szymczyk A, Forma E. Struktura i funkcje białka Klotho. Folia Medica Lodziensia. 2012; 39: 151–187.
  9. Hu MC, Kuro-o M, Moe OW. Renal and extrarenal actions of Klotho. Semin Nephrol. 2013; 33(2): 118–129.
  10. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390(6655): 45–51.
  11. Hu MC, Shi M, Zhang J, et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 2010; 24(9): 3438–3450.
  12. Sugiura H, Yoshida T, Mitobe M, et al. Klotho reduces apoptosis in experimental ischaemic acute kidney injury via HSP-70. Nephrol Dial Transplant. 2010; 25(1): 60–68.
  13. Sugiura H, Tsuchiya K, Nitta K. Circulating levels of soluble α-Klotho in patients with chronic kidney disease. Clin Exp Nephrol. 2011; 15(5): 795–796.
  14. Hu MC, Kuro-o M, Moe OW, et al. Secreted klotho and chronic kidney disease. Adv Exp Med Biol. 2012; 728: 126–157.
  15. Chu WM. Tumor necrosis factor. Cancer Lett. 2013; 328(2): 222–225.
  16. Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010; 20(2): 87–103.
  17. Clark IA. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev. 2007; 18(3-4): 335–343.
  18. Xu C, Chang A, Hack BK, et al. TNF-mediated damage to glomerular endothelium is an important determinant of acute kidney injury in sepsis. Kidney Int. 2014; 85(1): 72–81.
  19. Sanchez-Niño MD, Benito-Martin A, Gonçalves S, et al. TNF superfamily: a growing saga of kidney injury modulators. Mediators Inflamm. 2010; 2010.
  20. Speeckaert MM, Speeckaert R, Laute M, et al. Tumor necrosis factor receptors: biology and therapeutic potential in kidney diseases. Am J Nephrol. 2012; 36(3): 261–270.
  21. Keller CR, Odden MC, Fried LF, et al. Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. Kidney Int. 2007; 71(3): 239–244.
  22. Lee BT, Ahmed FA, Hamm LL, et al. Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease. BMC Nephrol. 2015; 16: 77.
  23. Mian AN, Schwartz GJ. Measurement and Estimation of Glomerular Filtration Rate in Children. Adv Chronic Kidney Dis. 2017; 24(6): 348–356.
  24. Gamrot Z, Adamczyk P, Świętochowska E, et al. Fibroblast growth factor 21 (FGF21) in children and adolescents with chronic kidney disease. Physiol Res. 2020; 69(3): 451–460.
  25. Mencke R, Hillebrands JL. NIGRAM consortium. The role of the anti-ageing protein Klotho in vascular physiology and pathophysiology. Ageing Res Rev. 2017; 35: 124–146.
  26. Maekawa Y, Ishikawa K, Yasuda O, et al. Klotho suppresses TNF-alpha-induced expression of adhesion molecules in the endothelium and attenuates NF-kappaB activation. Endocrine. 2009; 35(3): 341–346.
  27. He T, Xiong J, Huang Y, et al. Klotho restrain RIG-1/NF-κB signaling activation and monocyte inflammatory factor release under uremic condition. Life Sci. 2019; 231: 116570.
  28. Sági B, Peti A, Lakatos O, et al. Pro- and anti-inflammatory factors, vascular stiffness and outcomes in chronic hemodialysis patients. Physiol Int. 2020 [Epub ahead of print].
  29. Okamura DM, Himmelfarb J. Tipping the redox balance of oxidative stress in fibrogenic pathways in chronic kidney disease. Pediatr Nephrol. 2009; 24(12): 2309–2319.
  30. Tang J, Yan H, Zhuang S. Inflammation and oxidative stress in obesity-related glomerulopathy. Int J Nephrol. 2012; 2012: 608397.
  31. Jovinge S, Ares MP, Kallin B, et al. Human monocytes/macrophages release TNF-alpha in response to Ox-LDL. Arterioscler Thromb Vasc Biol. 1996; 16(12): 1573–1579.
  32. Rapa SF, Di Iorio BR, Campiglia P, et al. Inflammation and Oxidative Stress in Chronic Kidney Disease-Potential Therapeutic Role of Minerals, Vitamins and Plant-Derived Metabolites. Int J Mol Sci. 2019; 21(1).
  33. Odima A, Elhana NA, Mohamed W, et al. The study of oxidative status in children with end stage renal disease on regular hemodialysis. Egypt J Hosp Med. 2019; 74(5): 1111–1122.
  34. Dalton GD, Xie J, An SW, et al. New Insights into the Mechanism of Action of Soluble Klotho. Front Endocrinol (Lausanne). 2017; 8: 323.
  35. Goral J, Garanty-Bogacka B, Krupa B, et al. α a wybrane parametry gospodarki lipidowej u dzieci z nadwagą i otyłością prostą TNF α and selected lipid parameters in overweight and obese children. Endokrynol Ped. 2004; 3: 27–36.
  36. Jacobson MH, Liu M, Wu Y, et al. Oxidant stress and renal function among children with chronic kidney disease: a repeated measures study. Sci Rep. 2020; 10(1): 3129.
  37. Greenberg JH, Abraham AG, Xu Y, et al. CKD Biomarkers Consortium. Plasma Biomarkers of Tubular Injury and Inflammation Are Associated with CKD Progression in Children. J Am Soc Nephrol. 2020; 31(5): 1067–1077.
  38. Bae E, Cha RH, Kim YC, et al. Circulating TNF receptors predict cardiovascular disease in patients with chronic kidney disease. Medicine (Baltimore). 2017; 96(19): e6666.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl